Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone

Transfusion

Volumn 41, Issue 8, 2001, Pages 1037-1044

  Stroncek, David F ^a,b   Yau, Yu Ying ^a   Oblitas, Jaime ^a   Leitman, Susan F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; BLOOD; BLOOD CELL COUNT; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GRANULOCYTE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; STEM CELL MOBILIZATION;

ADULT; BLOOD; BLOOD CELL COUNT; BLOOD COMPONENT REMOVAL; BLOOD PRESSURE; BODY WEIGHT; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0035432392     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41081037.x     Document Type: Article

References (21)

1. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993;81:1675-8.
2. Strauss RG. Clinical perspectives of granulocyte transfusions: efficacy to date. J Clin Apheresis 1995;10:114-8.
3. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-8.
4. Leitman SF, Oblitas JM. Optimization of granulocytapheresis mobilization regimens using granulocyte colony stimulating factor (G-CSF) and dexamethasone (DEXA) (abstract). Transfusion 1997;37(Suppl):67S.
5. Liles WC, Huang JE, Llewellyn C, et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997;37:182-7.
6. Hester JP, Dignani MC, Anaissie EJ, et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 1995;10:188-93.
7. Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion 2000;40:642-4.
8. Jendiroba DB, Lichtiger B, Anaissie E, et al. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion 1998;38:722-8.
9. Leitman SF, Oblitas JM, Emmons R, et al. Clinical efficacy of daily G-CSF-recruited granulocyte transfusions in patients with severe neutropenia and life-threatening infections (abstract). Blood 1996;88:331a.
10. Adkins D, Goodgold H, Hendershott L, et al. Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997;19:809-12.
11. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000;95:3302-9.
12. Dale DC, Liles WC, Llewellyn C, et al. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion 1998;38:713-21.
13. Adkins DR, Goodnough LT, Shenoy S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 2000;95:3605-12.
14. Adkins D, Spitzer G, Johnson M, et al. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion 1997;37:737-48.
15. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and the collection of peripheral blood stem cells. Transfusion 1996;36:601-10.
16. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-5.
17. Stroncek DF, Clay ME, Jaszcz W, et al. Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 1999;9:37-50.
18. Anderlini P, Przepiorka D, Seong D, et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996;94:155-8.
19. Stroncek DF, Clay ME, Smith J, et al. Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors. Transfusion 1996;36:596-600.
20. Menitove JE, ed. Standards for blood banks and transfusion services. 20th ed. Bethesda: American Association of Blood Banks, 2000.
21. McCullough J, Clay M, Herr G, et al. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999;39:1136-40.